Critères d'inclusion : Men and women, aged 18 years or older.
Documented failure to achieve at least PR with, or documented disease progression after, the most recent treatment regimen.
Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy.
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
Critères de non-inclusion : History of central nervous system lymphoma (either primary or metastatic).
Prior treatment with idelalisib, other selective PI3Kδ inhibitors, or a pan PI3K inhibitor.
Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of first dose of study treatment.
Active graft-versus-host disease.
Liver disease: Subjects positive for hepatitis B surface antigen or hepatitis B core antibody will be eligible if they are negative for HBV-DNA. Subjects positive for anti-HCV antibody will be eligible if they are negative for HCV-RNA.